Current trial status
The first subject was included in September 2021. 40 subjects have been randomised and 28 have completed 13 weeks follow-up (Visit 3) by December 25, 2022. The second interim analysis will be performed when 40 subjects have completed Visit 3, according to current plan, Q1 2023.